Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,393,651	$ 3,075,502
Short-term investments – available for sale	8,689,630	10,075,058
Prepaid clinical trial costs	1,732,789	541,603
Prepaid expenses and other current assets	447,932	282,666
Total current assets	14,264,002	13,974,829
Deferred public offering and other financing costs	17,568	521,538
Deposits	39,341	39,341
Total assets	14,320,911	14,535,708
Current liabilities:
Accounts payable	1,304,711	1,203,888
Other accrued liabilities	2,418,355	1,237,122
Accrued interest, current	59,333	34,894
Convertible notes payable, current (net of discount of $919,184 and $675,589 at June 30, 2017 and December 31, 2016, respectively)	3,050,427	3,269,582
Debt conversion feature liability, current	894,152	731,048
Total current liabilities	7,726,978	6,476,534
Deferred rent	6,054	16,307
Total long-term liabilities	6,054	16,307
Total liabilities	7,733,032	6,492,841
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at June 30, 2017 and December 31, 2016; no shares issued and outstanding at June 30, 2017 and December 31, 2016
Common stock, $0.00001 par value: 300,000,000 shares authorized at June 30, 2017 and December 31, 2016; 27,697,284 and 20,823,873 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	277	208
Additional paid-in capital	77,264,402	68,326,818
Accumulated deficit	(70,670,801)	(60,277,267)
Accumulated other comprehensive loss	(5,999)	(6,892)
Total stockholders’ equity	6,587,879	8,042,867
Total liabilities and stockholders’ equity	$ 14,320,911	$ 14,535,708